Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

V Müller; M Banys-Paluchowski; T W P Friedl; P A Fasching; A Schneeweiss; A Hartkopf; D Wallwiener; B Rack; F Meier-Stiegen; J Huober; M Rübner; O Hoffmann; L Müller; W Janni; P Wimberger; B Jäger; K Pantel; S Riethdorf; N Harbeck; T Fehm; DETECT Study Group

doi:10.1016/j.esmoop.2021.100299

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

Standard

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. / Müller, V; Banys-Paluchowski, M; Friedl, T W P; Fasching, P A; Schneeweiss, A; Hartkopf, A; Wallwiener, D; Rack, B; Meier-Stiegen, F; Huober, J; Rübner, M; Hoffmann, O; Müller, L; Janni, W; Wimberger, P; Jäger, B; Pantel, K ; Riethdorf, S; Harbeck, N; Fehm, T; DETECT Study Group.

In: ESMO OPEN, Vol. 6, No. 6, 100299, 12.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Müller, V, Banys-Paluchowski, M, Friedl, TWP, Fasching, PA, Schneeweiss, A, Hartkopf, A, Wallwiener, D, Rack, B, Meier-Stiegen, F, Huober, J, Rübner, M, Hoffmann, O, Müller, L, Janni, W, Wimberger, P, Jäger, B, Pantel, K , Riethdorf, S, Harbeck, N, Fehm, T & DETECT Study Group 2021, 'Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program', ESMO OPEN, vol. 6, no. 6, 100299. https://doi.org/10.1016/j.esmoop.2021.100299

APA

Müller, V., Banys-Paluchowski, M., Friedl, T. W. P., Fasching, P. A., Schneeweiss, A., Hartkopf, A., Wallwiener, D., Rack, B., Meier-Stiegen, F., Huober, J., Rübner, M., Hoffmann, O., Müller, L., Janni, W., Wimberger, P., Jäger, B., Pantel, K., Riethdorf, S., Harbeck, N., ... DETECT Study Group (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO OPEN, 6(6), [100299]. https://doi.org/10.1016/j.esmoop.2021.100299

Vancouver

Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO OPEN. 2021 Dec;6(6). 100299. https://doi.org/10.1016/j.esmoop.2021.100299

Bibtex

@article{a5434c0de1ff418e929f0e605a628732,

title = "Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program",

abstract = "BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors.PATIENTS AND METHODS: Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining).RESULTS: Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS.CONCLUSION: CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.",

author = "V M{\"u}ller and M Banys-Paluchowski and Friedl, {T W P} and Fasching, {P A} and A Schneeweiss and A Hartkopf and D Wallwiener and B Rack and F Meier-Stiegen and J Huober and M R{\"u}bner and O Hoffmann and L M{\"u}ller and W Janni and P Wimberger and B J{\"a}ger and K Pantel and S Riethdorf and N Harbeck and T Fehm and {DETECT Study Group}",

year = "2021",

month = dec,

doi = "10.1016/j.esmoop.2021.100299",

language = "English",

volume = "6",

journal = "ESMO OPEN",

issn = "2059-7029",

publisher = "BMJ PUBLISHING GROUP",

number = "6",

}

RIS

TY - JOUR

T1 - Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

AU - Müller, V

AU - Banys-Paluchowski, M

AU - Friedl, T W P

AU - Fasching, P A

AU - Schneeweiss, A

AU - Hartkopf, A

AU - Wallwiener, D

AU - Rack, B

AU - Meier-Stiegen, F

AU - Huober, J

AU - Rübner, M

AU - Hoffmann, O

AU - Müller, L

AU - Janni, W

AU - Wimberger, P

AU - Jäger, B

AU - Pantel, K

AU - Riethdorf, S

AU - Harbeck, N

AU - Fehm, T

AU - DETECT Study Group

PY - 2021/12

Y1 - 2021/12

N2 - BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors.PATIENTS AND METHODS: Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining).RESULTS: Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS.CONCLUSION: CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.

AB - BACKGROUND: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors.PATIENTS AND METHODS: Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining).RESULTS: Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS.CONCLUSION: CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.

U2 - 10.1016/j.esmoop.2021.100299

DO - 10.1016/j.esmoop.2021.100299

M3 - SCORING: Journal article

C2 - 34839105

VL - 6

JO - ESMO OPEN

JF - ESMO OPEN

SN - 2059-7029

IS - 6

M1 - 100299

ER -